Russia has already approved two COVID-19 vaccines, Sputnik V and EpiVacCorona, which were also granted approval before seeing any late-stage trial results

As part of the review process, Dr Reddy's will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by 21st February 2021.

With no relief in sight from incessant rise in petrol and diesel prices, people turned to Twitter to vent their frustrations on the matter; The central government is set to notify the rules under new labour codes, which will have an impact on employees' cost to company (CTC) as well as employers' wage bills; Vaccination drive against COVID-19 and improving economic indicators have enthused employers to recruit. Watch this and more on News Blast.Also Read: Amazon to manufacture Fire TV Stick in India from this year

Revival in job market: January sees 50% rise in vacancies over December Vaccination drive against COVID-19 and improving economic indicators has enthused employers to recruit. This was evident in a survey which showed job openings increased almost 50 per cent in January as compared to December. Vacancies in January rose to 265,000 from 180,000 in December, according to Xpheno's Active Job Outlook survey. COVID-19 vaccine: Russia's Sputnik V may be approved by India in next few weeks Ind...

Earlier, Dr Reddy's had said it expects to roll out Sputnik V vaccine in India in March via Emergency Use Authorisation (EUA) after the completion of Phase 3 trials.

External Affairs Minister S Jaishankar said some poor countries are being supplied the vaccine on a grant basis, while some nations wanted it on par with the price that the Indian government pays to the vaccine makers

India boasts one of the biggest pharmaceutical industries globally and several countries have already approached it for procuring COVID-19 vaccines

Earlier, The Lancet had stated that Russia's experimental COVID-19 vaccine Sputnik V is 91.6 per cent affective against coronavirus infection. These results are based on Phase 3 trials of the vaccine in which 20,000 people had participated

Russia's COVID-19 vaccine, Sputnik V, has shown 91.6 per cent efficacy in phase 3 trials with no serious side effects, as per an interim analysis published in The Lancet Journal; Oxford Languages has named 'Aatmanirbharta' as its Hindi Word of the Year 2020; Alibaba Group founder Jack Ma has been delisted from \"Chinese entrepreneurial leaders\" list published by the country's official state media. Watch this and more on News Blast. Also Read: RBI releases framework for risk-based internal audit of NBFCs, UCBs

The pharma stock touched an intraday high of Rs 4,759.1 rising 6.13% against previous close of Rs 4,484.25 on BSE

The Gam-COVID-Vac, called Sputnik V, is a two-part vaccine that includes two adenovirus vectors - recombinant human adenovirus type 26 (rAd26-S) and recombinant human adenovirus type 5 (rAd5-S).

Sputnik V is undergoing Phase-3 trials in India currently which is expected to be completed by February

COVID-19 vaccination drive: 1 million jabs administered in India in six days India took only 6 days to administer one million Covid-19 vaccine doses, a count which is higher than that of countries like the US and the UK, the Union Health Ministry said on Sunday as the number of beneficiaries who have received the anti-coronavirus shots inched close to 16 lakh. The UK took 18 days whereas the US took 10 days to reach the one million mark, the ministry said. Budget 2021: COVID-19 crisis emp...

The government has given a go-ahead to a local pharmaceutical company for the import and distribution of the Russia-developed Sputnik V, the Dawn newspaper quoted an official as saying

Dmitriev said Sputnik V's $10 price tag is not only affordable but also half to one-third of other vaccines and has an efficacy rate of more than 90 per cent

Russia began testing EpiVacCorona, which is being developed by Siberia's Vector Institute, in November

Sputnik V vaccine phase 3: The Data and Safety Monitoring Board (DSMB) had reviewed the safety data from phase 2 trials of the vaccine and stated that there were no safety concerns attached to the jab earlier this week

Coronavirus vaccine in India: Adar Poonawalla, CEO of Serum Institute of India that is manufacturing Covishield had said that the company is ready to roll out its vaccine in the coming weeks

US Vice President-elect Kamala Harris received a COVID-19 vaccine shot on Tuesday, as the incoming Joe Biden administration seeks to boost confidence in the inoculation. Argentina, on the other hand, has shown  a green light for the emergency use of the Russian vaccine, Sputnik V, with Ireland beginning the mass vaccination drive for the Pfizer-BioNTech vaccine. Watch the video for more.

Russia's Gamaleya centre had earlier invited researchers from the University of Oxford to add a component of its vaccine to a component of AstraZeneca's, informed Alexander Gintsburg, Gamaleya centre's head